Joinn Laboratories(China)Co.,Ltd.

Research Joinn Laboratories(China)Co.,Ltd. (6127.HK) on Bullrun: market cap HKD 20.56B, P/E 18.7, dividend yield 0.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is HKD 20.56B; P/E is 18.7; dividend yield is 0.5%.

Peer valuation comparison

Latest P/E is 18.67x versus a Healthcare sector median of 21.69x (13.9% below).

Latest dividend yield is 0.52% versus a Healthcare sector median of 2.41% (78.4% below).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18HKD 20.56B18.70.5%0.14

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.14 HKD, yield 0.5%.

About Joinn Laboratories(China)Co.,Ltd.

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Joinn Laboratories(China)Co.,Ltd.'s market cap?

Joinn Laboratories(China)Co.,Ltd.'s market capitalization is HKD 20.56B.

What is Joinn Laboratories(China)Co.,Ltd.'s P/E ratio?

Joinn Laboratories(China)Co.,Ltd.'s price-to-earnings (P/E) ratio is 18.7.

Does Joinn Laboratories(China)Co.,Ltd. pay a dividend?

Joinn Laboratories(China)Co.,Ltd. has a dividend yield of 0.5%.

What does Joinn Laboratories(China)Co.,Ltd. do?

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies.